Insider Transactions in Q3 2023 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 14
2023
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,500
-1.58%
|
$85,000
$34.86 P/Share
|
|
Sep 13
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$425,000
$34.9 P/Share
|
|
Sep 13
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$75,000
$6.67 P/Share
|
|
Aug 25
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$412,500
$33.99 P/Share
|
|
Aug 25
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+1.36%
|
$87,500
$7.32 P/Share
|
|
Aug 21
2023
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
6,020
-24.85%
|
$192,640
$32.02 P/Share
|
|
Aug 21
2023
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,020
+19.9%
|
$36,120
$6.72 P/Share
|
|
Aug 11
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-1.38%
|
$400,000
$32.37 P/Share
|
|
Aug 11
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+1.35%
|
$100,000
$8.81 P/Share
|
|
Aug 10
2023
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,500
-1.56%
|
$77,500
$31.7 P/Share
|
|
Aug 01
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-1.39%
|
$400,000
$32.63 P/Share
|
|
Aug 01
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+1.36%
|
$112,500
$9.65 P/Share
|
|
Jul 13
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$437,500
$35.28 P/Share
|
|
Jul 13
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$112,500
$9.65 P/Share
|
|
Jul 13
2023
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,500
-1.53%
|
$87,500
$35.37 P/Share
|
|
Jul 07
2023
|
Muna Bhanji Director |
SELL
Open market or private sale
|
Direct |
2,000
-12.48%
|
$68,000
$34.12 P/Share
|
|
Jul 03
2023
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
187
+1.1%
|
$6,171
$33.36 P/Share
|
|
Jul 03
2023
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
636
+2.01%
|
$20,988
$33.36 P/Share
|
|
Jul 03
2023
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
374
+1.96%
|
$12,342
$33.36 P/Share
|
|
Jul 03
2023
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
374
+2.01%
|
$12,342
$33.36 P/Share
|
|
Jul 03
2023
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
374
+2.01%
|
$12,342
$33.36 P/Share
|
|
Jul 03
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$400,000
$32.6 P/Share
|
|
Jul 03
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$112,500
$9.65 P/Share
|
|
Jul 03
2023
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
374
+3.31%
|
$12,342
$33.36 P/Share
|